Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,651,330 papers from all fields of science
Search
Sign In
Create Free Account
SK&F 93319
Known as:
SK&F-93319
, SKF 93319
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
icotidine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Antinociceptive effects of H1- and H2-antihistaminics in mice.
N. Abacıoğlu
,
A. Bediz
,
I. Çakıcı
,
B. Tunctan
,
I. Kanzik
General Pharmacology
1993
Corpus ID: 4929734
1987
1987
Dose effects of the histamine h 1 and h 2 receptor antagonist skf 93319 on cardiovascular deterioration during circulatory shock
Michael F. Wilson
,
M. Lerner
,
+4 authors
D. Brackett
1987
Corpus ID: 86698424
1986
1986
Icotidine, an antagonist of histamine at both H1 and H2 receptors.
C. Ganellin
,
R. Blakemore
,
+7 authors
A. C. Rasmussen
New England and regional allergy proceedings
1986
Corpus ID: 5544179
SK&F 93319 (icotidine), 2-[4-(3-methoxypyrid-2-yl)butylamino]-5-[(6-methylpyrid-3-yl )-methyl]- pyrimidin-4-one trihydrochloride…
Expand
1984
1984
Cardiovascular studies with SK&F 93319, an antagonist of histamine at both H1‐ and H2‐receptors
C. A. Harvey
,
D. Owen
British Journal of Pharmacology
1984
Corpus ID: 24036114
1 Cardiovascular studies have been made in anaesthetized cats with SK&F 93319, an antagonist of histamine at both H1‐ and H2…
Expand
1984
1984
The pharmacokinetics in man of SK&F 93319--a new antagonist of histamine H1 and H2 receptors.
P. Johnson
,
R. Griffiths
,
+4 authors
W. L. Burland
Xenobiotica; the fate of foreign compounds in…
1984
Corpus ID: 6846451
SK&F 93319, a potent histamine H1- and H2-receptor antagonist, is rapidly absorbed with a low rate of plasma clearance primarily…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE